SG293 Preclinical Study Shows Dose-Dependent CAR T Expansion and Deep B Cell Depletion
SANA•Preclinical NHP studies showed a single intravenous dose of SG293 achieved dose-dependent CAR T cell expansion and complete peripheral B cell depletion without lymphodepleting chemotherapy. Tissue analysis revealed no off-target delivery to liver, heart, or gonads and manageable CAR T-related toxicities, supporting clinical entry in non-Hodgkin lymphoma later this year.
1. Preclinical Efficacy Findings
In non-human primates, a single intravenous administration of the SG293 surrogate produced robust CAR T cell generation, with expansion correlating to dose. Complete peripheral B cell depletion was observed within three weeks, followed by a reset of the B cell compartment characterized by a naïve phenotype upon repopulation.
2. Safety and Specificity Profile
Post-necropsy analysis showed no evidence of fusogen delivery to non-target tissues such as liver, heart, or gonads. In vivo safety assessments indicated only mild, acetaminophen-managed infusion symptoms, and CAR T-related toxicities were consistent with expected autologous profiles.
3. SG293 Clinical Development Plans
Data support initiation of first-in-human studies of SG293 for non-Hodgkin lymphoma later this year. The differentiated fusogen platform enables off-the-shelf in vivo CAR T therapy without lymphodepletion, underpinning regulatory submissions and clinical trial design.
4. Future SG227 Program
Sana plans to advance SG227, a BCMA-targeted in vivo CAR T candidate, into clinical development by mid-2027 for multiple myeloma. The platform’s modular fusogen system also positions it for future expansion into B cell-mediated autoimmune disorders.
